drugset / Trial / NCT05346198
Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, multicenter, open-label study o evaluate the safety and efficacy of CART-BCMA in subjects with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2021-03-12
- Primary completion
- 2022-07-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CART-BCMA | Cell therapy | — | Intravenous |